There is always a first: Why US biotech Axiom will begin its IPO journey in Hong Kong

on

f5osjWw

Axiom Biosciences intends to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong (HKEX), positioning it as the first U.S. biotech with a primary listing in Hong Kong

Axiom plans to tap Hong Kong’s biotech listing regime and later pursue a secondary Nasdaq listing

The IPO is expected in 2027, subject to regulatory review and market conditions

Sources:

Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange

Why US biotech Axiom is starting its IPO journey in Hong ...

The Weekly Biopharmaceutical News Source for Asia-Pacific

IPO

STOCKS | US-Based Axiom Seeks Hong Kong IPO to Tap ...

Axiom Asia Private Capital's Post - LinkedIn

Asia

Latest News & Press Releases

Biotech at HKEX

New Listing Information - AP & PHIP

[PDF] Axbio International Limited 安序源科技* - HKEXnews

Chapter 18A Listing Biotech Companies on the Hong Kong

Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire